Matinas BioPharma Holdings Inc. (NYSE American: MTNB) Attends 31st Annual ROTH Conference
Matinas BioPharma (NYSE American: MTNB) is a clinical-stage biopharmaceutical company focused on (i) the development of MAT9001 for abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular and metabolic disease, and (ii) enabling the delivery of life-changing medicines using the company’s proprietary, lipid nano-crystal (“LNC”) platform technology, including development of MAT2203, the company’s lead antifungal platform drug candidate. In addition, the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate small molecules, nucleic acid polymers, vaccines and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. For more information, visit the…







